Is Big Pharma's Next Target Already in Play?
A small biotech may have cracked one of medicine's biggest problems-how to deliver cancer drugs safely and effectively. With patented technology and promising early data, it's already catching the attention of Big Pharma.
Shares Stats
| Shares Outstanding | 16,850,000 |
| Shares Float | 16,830,000 |
| Shares Short | 780,000 |
| Insider Holdings | 8% |
| Institution Holdings | 2.95% |
About Aptevo Therapeutics Inc
Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. Its lead clinical blood cancer candidate is mipletamig that is in Phase 1b/2 clinical trial for the treatment of acute myelogenous leukemia. The company also develops ALG.APV-527, a novel investigational bispecific ADAPTIR candidate that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer, head and neck, colorectal, pancreatic, breast, and other solid tumors; APVO603, a preclinical dual agonist bispecific ADAPTIR candidate to treat multiple solid tumors; APVO442, a preclinical bispecific candidate based on the ADAPTIR-FLEX platform technology for the treatment of multiple solid tumors; and APVO711, a preclinical dual mechanism bispecific ADAPTIR candidate to treat prostate cancer. It has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
General
| Name | Aptevo Therapeutics Inc |
| Ticker | APVO |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Currency | USD |
| Country | USA |
| Fiscal Year End | December |
| Full Time Employees | 37 |
Highlights
| Analyst Target | 21.00 |
| Market Cap | 22,700,000 |
| EBITDA | -26,468,000 |
Financials
| Curr Year EPS Estimate | -5.38 |
| Next Quarter EPS Estimate | -1.90 |
| Return on Assets | -0.79 |
| Return on Equity | -2.43 |
| Earnings Per Share | 1,950.74 |
| Gross Profit | 345,000 |
| Quarterly Revenue Growth | -1 |
Valuation
| Trailing PE | 0.00 |
| Forward PE | 3.94 |
| Price/Sales (Trailing 12 Mt.) | 1.61 |
| Price/Book (Most Recent Quarter) | 1.34 |
Earnings
AP Lifestyles Digest for week of Dec. 1
Here is the AP Lifestyles Digest for the week of Dec. 1. Note AP's Holiday Gift Guide Digest moved Nov. 12 and is included at the end.
Trump Has Some Tough Words For Marjorie Taylor Greene After Promising To 'Do Everything' He Can To Help Make Syria 'Successful'
Trump vows to make Syria successful after meeting with former al Qaeda commander, amid extended sanctions relief and GOP criticism.
Weiss Gold Veteran Makes Shocking New Call - Ad
Weiss expert Sean Brodrick went out on a limb last year and declared a historic event would send the yellow metal to $3,150. People laughed at him at the time, but he was off by just two days. Now, Sean has a shocking new prediction for gold ... and reveals a little-known way to get ahead of this bull market.
Space forecasters say severe solar storms could hit Earth and trigger auroras
NEW YORK (AP) — Space weather forecasters issued an alert on Tuesday for incoming severe that could produce and temporarily disrupt communications.
China's 'Singles' Day' shopping festival a gauge of Beijing's effort to get consumers to spend more
HONG KONG (AP) — Alice Zhang, a 29-year-old marketer in the southern Chinese city of Guangzhou, has spent only roughly half what she did last year during the festival, switching to cheaper choices and giving up on buying new shoes after pay was cut by more than 20%.
First Drug to Show Breakthrough Myocarditis Data. Analysts See Potential 7-10x Upside. - Ad
This biotech just delivered a medical first in myocarditis and has a Phase 3 trial fully funded into 2027. Wall Street targets imply massive revaluation ahead.
Marjorie Taylor Greene Buys Blue Chip Stock Near 52-Week Low
Marjorie Taylor Greene is known for buying multiple stocks at a time, based on recent disclosures. A new filing shows one stock bought in November.
Chuck Schumer Says 41-Day Shutdown Has Exposed Trump's 'Cruelty,' Accuses President Of Holding Innocent Kids, Veterans As 'Political Hostages'
Schumer condemns Trump's 'cruelty' behind longest shutdown in U.S. history, as thousands of Americans suffer from furloughs and disrupted services.
$270,000 Drug. One Competitor. Billion-Dollar Market. - Ad
Phase 3 trial targets recurrent pericarditis with an oral therapy that could disrupt the only approved treatment. And their heart failure program launches in 2026.
Trump commutes prison sentence for former private equity executive David Gentile
HALLANDALE BEACH, Fla. (AP) — President has commuted the prison sentence of former investment manager David Gentile, who was convicted of defrauding investors — the latest in a Trump has taken in .
Asian shares are mostly lower despite Wall St rally and a potential end to the US shutdown
BANGKOK (AP) — Asian shares were mostly lower on Tuesday as the recent rebound fueled by buying of technology shares lost steam.
A Tiny Biotech Just Posted 10× Stronger Cancer Results - Ad
Early studies show this breakthrough delivery platform would make cancer treatments safer and more powerful. Now, with Big Pharma watching closely, investors are starting to take notice of what could be the next major biotech story.
Ukrainian Naval Drones Cripple Two Russian Oil Tankers In Black Sea, Disrupt Moscow's Shadow‑Fleet Operations
Ukrainian naval drones struck 2 sanctioned tankers in Black Sea, critically damaging both and crippling a key Russian oil‑transport route.
Marjorie Taylor Greene Goes Bargain Shopping, Discloses Buying These Two Stocks At 52-Week Lows
Congresswoman Marjorie Taylor Greene disclosed some new stocks recently. Unlike past trades in 2024 and 2025, the latest disclosure is rather unique.
The Smart Money Copper Trade - Ad
Quebec discovery. Strong grades. Roads and hydro in place. Funding secured for a busy drill calendar. Each assay can build scale and tighten the window for early entries as EVs and data centers pull harder on copper. Do not wait.
Donald Trump Nullifies 92% Of Joe Biden's Autopen-Signed Documents: 'Cancelling All Executive Orders And Anything Else'
Trump moved to invalidate what he claims are most of Biden's autopen-signed actions, sparking political backlash and renewed debate over the legality and precedent of using mechanical signatures for presidential documents.
How Tyson's Chicken Business Will Offset Beef Weakness
Tyson shares rise as pricing catch-up expected to ease cost pressures; chicken strength offsets beef headwinds amid stable feed costs.
Trump Signs Law to Launch Dollar 2.0 - Ad
Trump just signed law S.1582, unleashing the biggest money shift in 100+ years. For the first time since 1913, private firms - not the Fed - can mint a "Dollar 2.0." Treasury says it could drain $6.6T from banks and pay 10X current savings rates. Early investors in minting firms could see 40X returns by 2032.
In Trump-dominated media world, editing video takes on new significance — as BBC uproar shows
In the space of a few months, one of the more straightforward journalistic tasks — editing tape for broadcast — has been behind a $16 million legal settlement, a network's change in how it offers interviews on a news show and, now, the resignation of two top leaders at the BBC.
Japan's SoftBank says it has sold its shares in Nvidia for $5.8 billion
TOKYO (AP) — Japanese technology company SoftBank Group Corp. said Tuesday that it has sold all the Nvidia Corp. shares that it owned for $5.83 billion, while it reported higher than expected profit in the first half of this fiscal year.
Urgent Copper Stock With Strong Catalysts - Ad
Quebec discovery. Strong grades. Roads and hydro in place. Funding secured for a busy drill calendar. Each assay can build scale and tighten the window for early entries as EVs and data centers pull harder on copper. Do not wait.
XRP Jumps 10% In A Week As First-Ever Spot ETF Eyes Thursday Launch
XRP (CRYPTO: XRP) surged 10% over the past seven days amid mounting anticipation for the first-ever XRP ETF, which could launch as early as this week.
Warren Buffett Won't Buy Gold, And This Valuation Guru Agrees: 'It's A Collectible, Not An Asset'
Why don't Buffett & Damodaran buy gold? The valuation guru explains why gold is a 'collectible,' not an asset you can value.
Copper Is Tight, Silver Is Rising - And This Early Nevada Play Hits the Timing Perfectly - Ad
AI, electrification, battery storage, and data centers are pushing copper and silver demand sharply higher, even as supply stays tight. This region in Nevada offers rare multi-metal potential, and a new company has secured land in a district the surging district. It's one of the cleanest timing setups in the sector right now.
Dogecoin Fakes A Rally Then Dumps 3%—But Why?
Dogecoin (CRYPTO: DOGE) fell close to 3% on Tuesday, as large holders shifted roughly $32 million worth of DOGE to exchanges, putting sellers back in control.
Analyst Sees Strong Medtronic Momentum Through 2026 With Buy Rating Intact
BofA expects Medtronic to post over 5% second-quarter revenue growth and maintain strong momentum through 2026, driven by robust procedure trends.
Copper, Silver, Gold, Tungsten - This Nevada Play Offers Multiple Shots on Goal - Ad
Most early-stage resource opportunities rely on one metal. This one doesn't. The Walker Lane belt hosts copper, silver, gold, and tungsten - and recent results across the district confirm all four. This startup has stepped in with multi-metal exposure, giving investors several potential ways to capture upside.
Why 12-Year-Old Mark Zuckerberg Built A Little Messaging Network For The Family Member Who Reportedly Wrote Him $100,000 Check To Start Facebook
Preteen Mark Zuckerberg's early coding projects, including the family messaging system ZuckNet, combined with strong family support and a reported $100,000 check from his father, foreshadowed his creation of Facebook and Meta's later rise to a $1.54 trillion company.
Weekend Round-Up: Airbus Chaos, BYD's Massive Recall, Tesla's Free FSD Rides, Rivian's Tax Credit Silver Lining And More
From emergency aircraft recalls to massive vehicle recalls in China, to free self-driving rides in Europe, the past week was buzzing in the auto and tech sector.
Is Big Pharma's Next Target Already in Play? - Ad
A small biotech may have cracked one of medicine's biggest problems-how to deliver cancer drugs safely and effectively. With patented technology and promising early data, it's already catching the attention of Big Pharma.
The Key to a Winning 401(k)
: when to start, how much to save, and where to invest. The investing decision has drawn more attention as government regulators work to open 401(k) plans to alternative assets such as .
Covet an Italian masterpiece, but shy of the millions? How about a digital copy at supercar prices
MILAN (AP) — The last person to get their hands on a painting attributed to Leonardo da Vinci shelled out Now, Italian cultural officials are making it possible to purchase a limited edition, certified digital copy of the Renaissance genius’ “Lady with Disheveled Hair’’ for roughly the price of a Lamborghini.
Weiss Gold Veteran Makes Shocking New Call - Ad
Weiss expert Sean Brodrick went out on a limb last year and declared a historic event would send the yellow metal to $3,150. People laughed at him at the time, but he was off by just two days. Now, Sean has a shocking new prediction for gold ... and reveals a little-known way to get ahead of this bull market.
Axon Enterprise: From TASER To AI-Powered Public Safety Platform
Axon Enterprise is executing an interesting transition from hardware vendor to high-margin SaaS and AI platform...
Gen Z Takes To 'Income Stacking' As One Pay Check Falls Short
Gen Zers are turning to income stacking to secure their financial future as they fear a single paycheck won't be enough. AI and broken social contract fuel the shift. Side hustles becoming core of young careers.
First Drug to Show Breakthrough Myocarditis Data. Analysts See Potential 7-10x Upside. - Ad
This biotech just delivered a medical first in myocarditis and has a Phase 3 trial fully funded into 2027. Wall Street targets imply massive revaluation ahead.
Elon Musk Says Bitcoin Is Based On Energy, The 'True Currency' — Tesla CEO Says His 'Interesting Side Quest' DOGE Is Still Going On
Tesla and SpaceX CEO reiterated in an interview aired Sunday that Bitcoin (CRYPTO: BTC) is based on energy, categorizing it among 
JPMorgan Forecasts Bitcoin Bottom, Anticipates $28.3 Trillion Challenge To Gold By 2026
Analysts at JPMorgan have pinpointed the lowest point of the ongoing Bitcoin (CRYPTO: BTC) price fall and also projected a substantial chall
$270,000 Drug. One Competitor. Billion-Dollar Market. - Ad
Phase 3 trial targets recurrent pericarditis with an oral therapy that could disrupt the only approved treatment. And their heart failure program launches in 2026.
Why Is Occidental Petroleum Stock Gaining Tuesday?
Analysts highlight OXY's robust earnings, production guidance, and expanded resource base as key growth drivers.
Information, charts or examples are for illustration and educational purposes only and not for individualized investment management This message contains commercial elements, such as advertising. We only send these offers to those who have opted in to our newsletter. Past performance is not indicative of future results. For these reasons we strongly suggest trading in a DEMO/Simulated account. The information provided by us is for educational and informational purposes only. We make no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended and have not determined if the statements and opinions of the advertiser are accurate, correct or truthful. If you use, act upon or make decisions in reliance on information contained or any external source linked within it, you do so at your own peril and agree to hold us, our officers, directors, shareholders, affiliates and agents without fault.